Jubilant Pharmova Limited today announced that the United States Food and Drug Administration (USFDA) has concluded audit of the Radiopharmaceutical manufacturing facility on April, 23, 2024 at Montreal, Canada of Jubilant Draximage, a subsidiary of its wholly owned subsidiary Jubilant Pharma Limited.

The USFDA has issued 5 observations pursuant to the completion of audit. The company will submit an action plan on the observations.